Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection
Molecular Biotechnology · 2025-09 · 67 (9) · 3415-3427
DOI: 10.1007/s12033-024-01277-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biotechnology, online erschienen am 13.09.2024. Verfasst von Nurshamimi Nor Rashid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
Angiotensin-converting enzyme-2 (ACE2) downregulation represents a detrimental factor in people with a baseline ACE2 deficiency associated with older age, hypertension, diabetes, and cardiovascular diseases. Human coronaviruses, including HCoV-NL63, SARS-CoV-1, and SARS CoV-2 infect target cells via binding of viral spike (S) glycoprotein to the ACE2, resulting in ACE2 downregulation through yet unidentified mechanisms. This downregulation disrupts the enzymatic activity of ACE2, essential in protecting against organ injury by cleaving and disposing of Angiotensin-II (Ang II), leading to the formation of Ang 1-7, thereby exacerbating the accumulation of Ang II. This accumulation activates the Angiotensin II type 1 receptor (AT1R) receptor, leading to leukocyte recruitment and increased proinflammatory cytokines, contributing to organ injury. The biological impacts and underlying mechanisms of ACE2 downregulation during SARS-CoV-2 infection have not been well defined. Therefore, there is an urgent need to establish a solid theoretical and experimental understanding of the mechanisms of ACE2 downregulation during SARS-CoV-2 entry and replication in the host cells. This review aims to discuss the physiological impact of ACE2 downregulation during coronavirus infection, the relationship between ACE2 decline and virus pathogenicity, and the possible mechanisms of ACE2 degradation, along with the therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
- Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
- Bergen Community College, Paramus, NJ, USA.
- Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia. rohanayusof@ucsiuniversity.edu.my.
- Institute of Biological Sciences, Faculty of Science, Universiti Malaya, 50603, Kuala Lumpur, Malaysia. Hussin.rothan@Pfizer.com.
- Pfizer, Pearl River, NY, USA. Hussin.rothan@Pfizer.com.
Zitieren
APA
Nor Rashid, N., Amrani, L., Alwan, A., Mohamed, Z., Yusof, R., & Rothan, H. (2025). Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection. Molecular Biotechnology, 67(9), 3415-3427. https://doi.org/10.1007/s12033-024-01277-5
Vancouver
Nor Rashid N, Amrani L, Alwan A, Mohamed Z, Yusof R, Rothan H. Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection. Molecular Biotechnology. 2025;67(9):3415-3427. doi:10.1007/s12033-024-01277-5
BibTeX
@article{NorRashid2025,
author = {Nor Rashid, Nurshamimi and Amrani, Lina and Alwan, Abdullah and Mohamed, Zulqarnain and Yusof, Rohana and Rothan, Hussin},
title = {Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection},
journal = {Molecular Biotechnology},
year = {2025},
volume = {67},
number = {9},
pages = {3415--3427},
doi = {10.1007/s12033-024-01277-5}
}
EUVIMED